Compare Dover Corp (DOV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Inovio Pharmaceuticals Inc — how do they compare? Dover Corp trades at $208.79 (market cap $28.07B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Dover Corp is far larger — about 357.4× Inovio Pharmaceuticals Inc's market cap, and Dover Corp pays a 1.01% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DOV | INO | |
|---|---|---|
Market Cap | $28.07B | $78.55M |
Sector | Industrials | Health |
52-Week High | $233.31 | $2.87 |
52-Week Low | $161.16 | $0.66 |
Enterprise Value | $29.58B | $49.56M |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $208.07, down 0.97% on the day, with strong analyst support showing 19 buy ratings and a $232.33 consensus price target. The company demonstrates solid fundamentals with consistent earnings beats, a 13.48% net income margin, and recent dividend increases. Technical indicators show a bearish short-term signal despite neutral oscillators, with key support at $205.
DOV presents a compelling investment case with strong profitability, dividend growth, and raised 2026 guidance, though near-term technical weakness and acquisition integration risks warrant monitoring. The stock offers approximately 11.7% upside to analyst targets with no sell ratings among 28 covering firms.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
